DIANT Pharma

DIANT Pharma is a private, pre-revenue technology and services company positioned as an enabler in the rapidly growing field of nanoparticle drug delivery, particularly for RNA therapeutics. Its primary business model is selling precision manufacturing equipment (from benchtop to pilot-scale systems) and offering contract R&D and manufacturing services to pharmaceutical innovators and CDMOs. The company's value proposition centers on replacing outdated batch processing with its continuous, closed-loop DIANT® Jet platform, which promises superior particle uniformity (PDI~0.05), linear scalability, and reduced development timelines to accelerate clients' time to market.

Proprietary DIANT® Jet technology for continuous, scalable manufacturing of lipid nanoparticles (LNPs) and other nanoparticles. Features inline monitoring and control for high uniformity (low PDI) and closed-loop processing.

DIANT competes with other specialized nanoparticle manufacturing equipment providers (e.g., Knauer, Microfluidics) and, more broadly, with CDMOs like Lonza and Thermo Fisher that offer LNP manufacturing services and may use proprietary processes. Its key differentiator is its claim of being the only fully integrated, continuous manufacturing system on the market.